REGENXBIO Inc. (NASDAQ:RGNX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of REGENXBIO Inc. (NASDAQ:RGNX) have received a consensus recommendation of “Moderate Buy” from the nine brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $30.3750.

Several research firms have recently weighed in on RGNX. Barclays began coverage on shares of REGENXBIO in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $37.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $34.00 price objective on shares of REGENXBIO in a research report on Thursday, January 29th. Royal Bank Of Canada raised their target price on REGENXBIO from $17.00 to $19.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of REGENXBIO in a research report on Thursday, January 22nd. Finally, Wall Street Zen cut REGENXBIO from a “hold” rating to a “sell” rating in a report on Saturday, January 31st.

REGENXBIO Trading Down 0.2%

REGENXBIO stock opened at $10.31 on Tuesday. REGENXBIO has a 12-month low of $5.03 and a 12-month high of $16.19. The stock has a market cap of $521.89 million, a P/E ratio of -2.97 and a beta of 1.05. The company has a 50-day moving average price of $13.43 and a 200 day moving average price of $11.43.

Institutional Trading of REGENXBIO

A number of institutional investors and hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC raised its position in REGENXBIO by 2,247.7% in the 1st quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company’s stock valued at $4,437,000 after purchasing an additional 594,161 shares in the last quarter. Jane Street Group LLC grew its holdings in REGENXBIO by 151.1% during the 1st quarter. Jane Street Group LLC now owns 414,067 shares of the biotechnology company’s stock worth $2,961,000 after acquiring an additional 249,156 shares in the last quarter. CWM LLC increased its position in shares of REGENXBIO by 75.4% in the 2nd quarter. CWM LLC now owns 46,816 shares of the biotechnology company’s stock valued at $384,000 after purchasing an additional 20,120 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of REGENXBIO in the 2nd quarter valued at $1,453,000. Finally, Savant Capital LLC purchased a new stake in shares of REGENXBIO during the 2nd quarter worth $226,000. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.